PARIS (Reuters) – French artificial heartmaker Carmat announced on Tuesday that it had carried out the first implant of its Aeson artificial heart in a woman.
The company said the procedure had been performed at the UofL Health – Jewish Hospital by University of Louisville physicians in the United States.
“This third implant in the U.S. was a landmark event not only because it allowed us to finalize the enrollment of the first cohort of patients of the EFS (early feasibility study), but very importantly because it is the first time ever that our device has helped a woman suffering from heart failure,” Carmat CEO Stephane Piat said in a statement.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.